Symbols / XNCR Stock $12.98 +4.26% Xencor, Inc.

Healthcare • Biotechnology • United States • NGM
XNCR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Bassil I. Dahiyat Ph.D.
Exch · Country NGM · United States
Market Cap 951.94M
Enterprise Value 553.08M
Income -91.92M
Sales 125.58M
FCF (ttm) -39.17M
Book/sh 8.84
Cash/sh 7.47
Employees 260
Insider 10d —
IPO Dec 03, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.27
PEG —
P/S 7.58
P/B 1.47
P/C —
EV/EBITDA -3.31
EV/Sales 4.40
Quick Ratio 6.02
Current Ratio 6.25
Debt/Eq 29.54
LT Debt/Eq —
EPS (ttm) -1.24
EPS next Y -3.04
EPS Growth —
Revenue Growth -46.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-02-25
ROA -12.14%
ROE -14.07%
ROIC —
Gross Margin -90.67%
Oper. Margin -189.92%
Profit Margin -73.20%
Shs Outstand 73.34M
Shs Float 53.86M
Insider Own 1.26%
Instit Own 119.42%
Short Float 21.74%
Short Ratio 11.43
Short Interest 11.30M
52W High 18.69
vs 52W High -30.55%
52W Low 6.92
vs 52W Low 87.57%
Beta 0.99
Impl. Vol. 29.57%
Rel Volume 0.80
Avg Volume 761.03K
Volume 609.27K
Target (mean) $28.42
Tgt Median $27.00
Tgt Low $13.00
Tgt High $43.00
# Analysts 12
Recom Strong_buy
Prev Close $12.45
Price $12.98
Change 4.26%
About

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$28.42
Mean price target
2. Current target
$12.98
Latest analyst target
3. DCF / Fair value
$-9.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.98
Low
$13.00
High
$43.00
Mean
$28.42

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 down JP Morgan Overweight → Neutral $13
2026-02-26 main Barclays Overweight → Overweight $27
2025-12-17 main Barclays Overweight → Overweight $26
2025-11-24 init Truist Securities — → Buy $29
2025-11-06 main JP Morgan Overweight → Overweight $18
2025-11-06 main RBC Capital Outperform → Outperform $19
2025-11-06 main Cantor Fitzgerald Overweight → Overweight $42
2025-10-29 up Barclays Underweight → Overweight $23
2025-10-27 main RBC Capital Outperform → Outperform $18
2025-09-03 down B of A Securities Buy → Neutral $12
2025-09-02 reit Wedbush Outperform → Outperform $26
2025-08-21 main RBC Capital Outperform → Outperform $15
2025-08-07 main Wells Fargo Overweight → Overweight $27
2025-08-07 main Wedbush Outperform → Outperform $26
2025-05-08 main Barclays Underweight → Underweight $6
2025-04-21 init William Blair — → Outperform —
2025-02-28 main Wells Fargo Overweight → Overweight $33
2024-12-12 init Wells Fargo — → Overweight $37
2024-12-02 up Piper Sandler Neutral → Overweight $30
2024-11-08 reit BMO Capital Outperform → Outperform $34
News
RSS: Latest XNCR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-10 CORNELISSEN BART JAN Chief Financial Officer — 3,499 $12.29 $42,990
2026-03-06 ECKERT CELIA E General Counsel — 5,011 $11.02 $55,952
2026-03-06 DESJARLAIS JOHN R Officer — 6,620 $11.02 $73,880
2026-03-06 DAHIYAT BASSIL ISHMAEL Chief Executive Officer — 21,476 $11.02 $240,017
2026-03-05 CORNELISSEN BART JAN Chief Financial Officer — 2,517 $11.25 $28,305
2026-03-03 ECKERT CELIA E General Counsel — 1,492 $11.90 $17,747
2026-03-03 DESJARLAIS JOHN R Officer — 2,663 $11.90 $31,677
2026-03-03 DAHIYAT BASSIL ISHMAEL Chief Executive Officer — 6,758 $11.90 $80,387
2026-03-02 ECKERT CELIA E General Counsel — 18,680 $0.00 $0
2026-03-02 CORNELISSEN BART JAN Chief Financial Officer — 19,458 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
125.58
+13.65%
110.49
-36.72%
174.62
+6.10%
164.58
Operating Revenue
125.58
+13.65%
110.49
-36.72%
174.62
+6.10%
164.58
Operating Expense
303.08
+4.91%
288.90
-5.89%
306.98
+24.26%
247.05
Research And Development
239.43
+5.16%
227.69
-10.22%
253.60
+27.08%
199.56
Selling General And Administration
63.64
+3.97%
61.22
+14.68%
53.38
+12.40%
47.49
General And Administrative Expense
63.64
+3.97%
61.22
+14.68%
53.38
+12.40%
47.49
Other Gand A
63.64
+3.97%
61.22
+14.68%
53.38
+12.40%
47.49
Total Expenses
303.08
+4.91%
288.90
-5.89%
306.98
+24.26%
247.05
Operating Income
-177.50
+0.51%
-178.41
-34.79%
-132.36
-60.49%
-82.47
Total Operating Income As Reported
-177.50
+0.51%
-178.41
-34.79%
-132.36
-60.49%
-82.47
EBITDA
-47.19
+74.65%
-186.17
-82.60%
-101.96
-123.12%
-45.70
Normalized EBITDA
-139.54
-3.88%
-134.32
-32.25%
-101.56
-47.21%
-68.99
Reconciled Depreciation
10.51
-13.17%
12.11
+5.30%
11.50
+30.67%
8.80
EBIT
-57.71
+70.90%
-198.28
-74.76%
-113.46
-108.20%
-54.49
Total Unusual Items
92.34
+278.09%
-51.85
-13027.09%
-0.40
-101.70%
23.30
Total Unusual Items Excluding Goodwill
92.34
+278.09%
-51.85
-13027.09%
-0.40
-101.70%
23.30
Special Income Charges
-9.17
+55.12%
-20.43
0.00
+100.00%
-0.14
Write Off
9.17
-55.12%
20.43
0.00
-100.00%
0.14
Net Income
-91.92
+60.48%
-232.62
-74.73%
-133.13
-141.27%
-55.18
Pretax Income
-89.63
+61.85%
-234.92
-96.37%
-119.63
-119.48%
-54.51
Net Non Operating Interest Income Expense
-4.40
+6.58%
-4.71
-135.83%
13.15
+173.07%
4.82
Interest Expense Non Operating
31.93
-12.87%
36.64
+493.22%
6.18
+47415.38%
0.01
Net Interest Income
-4.40
+6.58%
-4.71
-135.83%
13.15
+173.07%
4.82
Interest Expense
31.93
-12.87%
36.64
+493.22%
6.18
+47415.38%
0.01
Interest Income Non Operating
27.52
-13.80%
31.93
+65.18%
19.33
+300.23%
4.83
Interest Income
27.52
-13.80%
31.93
+65.18%
19.33
+300.23%
4.83
Other Income Expense
92.27
+278.12%
-51.80
-12060.09%
-0.43
-101.84%
23.15
Other Non Operating Income Expenses
-0.07
-246.00%
0.05
+261.29%
-0.03
+79.05%
-0.15
Gain On Sale Of Security
101.51
+423.07%
-31.42
-7854.94%
-0.40
-101.69%
23.43
Tax Provision
2.50
+54.85%
1.62
-88.16%
13.66
+1930.01%
0.67
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
19.39
+278.09%
-10.89
-13027.09%
-0.08
-101.70%
4.89
Net Income Including Noncontrolling Interests
-92.14
+61.05%
-236.54
-77.45%
-133.30
-141.56%
-55.18
Net Income From Continuing Operation Net Minority Interest
-91.92
+60.48%
-232.62
-74.73%
-133.13
-141.27%
-55.18
Net Income From Continuing And Discontinued Operation
-91.92
+60.48%
-232.62
-74.73%
-133.13
-141.27%
-55.18
Net Income Continuous Operations
-92.14
+61.05%
-236.54
-77.45%
-133.30
-141.56%
-55.18
Minority Interests
0.21
-94.54%
3.92
+2306.13%
0.16
0.00
Normalized Income
-164.88
+13.97%
-191.65
-44.30%
-132.82
-80.50%
-73.58
Net Income Common Stockholders
-91.92
+60.48%
-232.62
-74.73%
-133.13
-141.27%
-55.18
Diluted EPS
-1.24
+65.36%
-3.58
-72.12%
-2.08
-123.66%
-0.93
Basic EPS
-1.24
+65.36%
-3.58
-72.12%
-2.08
-123.66%
-0.93
Basic Average Shares
74.24
+14.14%
65.04
+7.50%
60.50
+1.43%
59.65
Diluted Average Shares
74.24
+14.14%
65.04
+7.50%
60.50
+1.43%
59.65
Diluted NI Availto Com Stockholders
-91.92
+60.48%
-232.62
-74.73%
-133.13
-141.27%
-55.18
Line Item Trend 2023-12-31
Total Assets
965.13
Current Assets
635.60
Cash Cash Equivalents And Short Term Investments
593.73
Cash And Cash Equivalents
53.79
Other Short Term Investments
539.93
Receivables
23.74
Accounts Receivable
23.74
Prepaid Assets
—
Other Current Assets
18.14
Total Non Current Assets
329.53
Net PPE
100.12
Gross PPE
136.34
Accumulated Depreciation
-36.23
Properties
0.00
Machinery Furniture Equipment
49.94
Construction In Progress
—
Other Properties
33.99
Leases
52.41
Goodwill And Other Intangible Assets
18.66
Other Intangible Assets
18.66
Investments And Advances
209.72
Other Non Current Assets
1.03
Total Liabilities Net Minority Interest
303.05
Current Liabilities
73.92
Payables And Accrued Expenses
42.77
Payables
19.20
Accounts Payable
13.91
Current Accrued Expenses
23.56
Total Tax Payable
5.29
Income Tax Payable
5.29
Current Debt And Capital Lease Obligation
31.15
Current Debt
27.71
Other Current Borrowings
27.71
Current Capital Lease Obligation
3.44
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Total Non Current Liabilities Net Minority Interest
229.13
Long Term Debt And Capital Lease Obligation
220.80
Long Term Debt
161.77
Long Term Capital Lease Obligation
59.02
Tradeand Other Payables Non Current
8.34
Non Current Deferred Liabilities
125.18
Non Current Deferred Revenue
125.18
Stockholders Equity
661.75
Common Stock Equity
661.75
Capital Stock
0.61
Common Stock
0.61
Preferred Stock
0.00
Share Issued
61.00
Ordinary Shares Number
61.00
Treasury Shares Number
0.00
Additional Paid In Capital
1,131.27
Retained Earnings
-471.42
Gains Losses Not Affecting Retained Earnings
1.29
Minority Interest
0.34
Other Equity Adjustments
1.29
Total Equity Gross Minority Interest
662.09
Total Capitalization
823.52
Working Capital
561.69
Invested Capital
851.23
Total Debt
251.94
Net Debt
135.69
Capital Lease Obligations
62.46
Net Tangible Assets
643.09
Tangible Book Value
643.09
Available For Sale Securities
209.72
Investmentin Financial Assets
209.72
Non Current Note Receivables
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-135.12
+33.17%
-202.19
-159.46%
-77.93
-418.26%
24.48
Cash Flow From Continuing Operating Activities
-135.12
+33.17%
-202.19
-159.46%
-77.93
-418.26%
24.48
Net Income From Continuing Operations
-92.14
+61.05%
-236.54
-77.45%
-133.30
-141.56%
-55.18
Depreciation Amortization Depletion
10.51
-13.17%
12.11
+5.30%
11.50
+30.67%
8.80
Depreciation And Amortization
10.51
-13.17%
12.11
+5.30%
11.50
+30.67%
8.80
Other Non Cash Items
-48.34
-59.49%
-30.31
-64.55%
-18.42
-241.34%
-5.40
Stock Based Compensation
43.23
-18.87%
53.28
-0.88%
53.76
+9.90%
48.91
Asset Impairment Charge
9.17
-55.12%
20.43
0.00
-100.00%
0.14
Operating Gains Losses
-14.39
-471.88%
3.87
+46.22%
2.65
+59.88%
1.66
Gain Loss On Investment Securities
-14.39
-38786.49%
-0.04
—
—
Unrealized Gain Loss On Investment Securities
-87.13
-377.28%
31.42
+7854.94%
0.40
+101.69%
-23.43
Gain Loss On Sale Of PPE
0.00
-100.00%
2.33
+83.82%
1.27
-16.09%
1.51
Change In Working Capital
47.45
+217.46%
-40.40
-311.15%
19.13
-60.85%
48.87
Change In Receivables
31.36
+186.83%
-36.11
-292.04%
18.80
-48.98%
36.86
Changes In Account Receivables
28.73
+187.94%
-32.67
-264.74%
19.83
-46.95%
37.39
Change In Prepaid Assets
9.44
+5837.74%
0.16
-96.88%
5.10
+704.89%
0.63
Change In Payables And Accrued Expense
9.84
+755.33%
-1.50
-117.34%
8.66
+287.17%
-4.63
Change In Accrued Expense
13.80
+417.37%
-4.35
-189.89%
4.84
+776.36%
-0.71
Change In Payable
-3.95
-238.95%
2.85
-25.64%
3.83
+197.78%
-3.91
Change In Account Payable
-3.95
-238.95%
2.85
-25.64%
3.83
+197.78%
-3.91
Change In Other Working Capital
-3.19
-8.32%
-2.94
+78.10%
-13.44
-183.97%
16.00
Investing Cash Flow
139.99
+1878.26%
-7.87
+92.91%
-111.06
+7.23%
-119.72
Cash Flow From Continuing Investing Activities
139.99
+1878.26%
-7.87
+92.91%
-111.06
+7.23%
-119.72
Net PPE Purchase And Sale
-3.15
+48.34%
-6.10
+66.95%
-18.45
+52.08%
-38.49
Purchase Of PPE
-3.15
+48.34%
-6.10
+66.95%
-18.45
+52.08%
-38.49
Sale Of PPE
0.00
0.00
-100.00%
0.00
0.00
Capital Expenditure
-3.15
+66.88%
-9.51
+55.24%
-21.25
+51.04%
-43.40
Net Investment Purchase And Sale
143.13
+8627.74%
1.64
+101.83%
-89.81
-10.45%
-81.32
Purchase Of Investment
-298.89
+49.77%
-595.05
+23.99%
-782.90
-101.82%
-387.93
Sale Of Investment
442.03
-25.92%
596.69
-13.91%
693.09
+126.05%
306.61
Net Intangibles Purchase And Sale
0.00
+100.00%
-3.42
-21.83%
-2.80
+42.91%
-4.91
Purchase Of Intangibles
0.00
+100.00%
-3.42
-21.83%
-2.80
+42.91%
-4.91
Net Other Investing Changes
—
—
—
5.00
Financing Cash Flow
8.23
-95.82%
197.15
+4.19%
189.22
+3218.47%
5.70
Cash Flow From Continuing Financing Activities
8.23
-95.82%
197.15
+4.19%
189.22
+3218.47%
5.70
Net Common Stock Issuance
0.00
-100.00%
201.26
0.00
0.00
Proceeds From Stock Option Exercised
9.96
+24.88%
7.97
+47.95%
5.39
-5.49%
5.70
Net Other Financing Charges
-1.73
+85.72%
-12.08
-106.57%
183.83
—
Changes In Cash
13.10
+201.49%
-12.91
-5761.40%
0.23
+100.25%
-89.54
Beginning Cash Position
41.26
-23.83%
54.17
+0.42%
53.94
-62.40%
143.48
End Cash Position
54.36
+31.75%
41.26
-23.83%
54.17
+0.42%
53.94
Free Cash Flow
-138.27
+34.69%
-211.70
-113.46%
-99.18
-424.22%
-18.92
Interest Paid Supplemental Data
0.01
-84.85%
0.03
+50.00%
0.02
+69.23%
0.01
Income Tax Paid Supplemental Data
7.31
+19.87%
6.10
0.00
-100.00%
0.70
Amortization Of Securities
-3.48
+78.30%
-16.04
-17.67%
-13.63
-10836.22%
0.13
Change In Income Tax Payable
—
—
13.63
0.00
Change In Tax Payable
—
—
13.63
0.00
Common Stock Issuance
0.00
-100.00%
201.26
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
201.26
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category